StreetInsider.com News Articles

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

Wed, 13 May 2026 09:00:00 -0400

CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B. Riley Securities Institutional Investor Conference, being held in Marina Del Rey, CA on Thursday, May 21, 2026, including a fireside chat from 9:00–9:40 a.m. PT.

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

Wed, 13 May 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

Wed, 13 May 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

Wed, 13 May 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

Wed, 13 May 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

Wed, 13 May 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call

Mon, 27 Apr 2026 09:00:00 -0400

CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its first quarter 2026 financial results on Thursday, May 7, 2026, to be followed by a conference call the same day at 5:30 p.m. (Eastern Time).

The conference call can be accessed live over the phone by dialing 1-800-225-9448 or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode

The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call

Mon, 27 Apr 2026 09:00:00 -0400

The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call

Mon, 27 Apr 2026 09:00:00 -0400

The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call

Mon, 27 Apr 2026 09:00:00 -0400

The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call

Mon, 27 Apr 2026 09:00:00 -0400

The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call

Mon, 27 Apr 2026 09:00:00 -0400

Oncology Institute generates $1.8 million in Medicare savings

Mon, 13 Apr 2026 09:02:10 -0400

The Oncology Institute of Hope and Innovation (NASDAQ: TOI) achieved $1.8 million in Medicare savings during Performance Period 3 of the Centers for Medicare & Medicaid Services' Enhancing Oncology Model through its California professional corporation, according to a company statement.

The savings equated to more than $6,400 per patient episode, representing an increase from Performance Period 2, when the company generated $1.1 million in savings, or more than $3,500 per episode.

For the second consecutive performance period, TOI earned the maximum score on avoidable emergency department visits and hospital admissions. The company attributed results to its High-Value Cancer Care program, which includes

Oncology Institute generates $1.8 million in Medicare savings

Mon, 13 Apr 2026 09:02:10 -0400

The savings equated to more than $6,400 per patient episode, representing an increase from Performance Period 2, when the company generated $1.1 million in savings, or more than $3,500 per episode.

The Oncology Institute Achieves $1.8 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 3, Marking Significant Period-Over-Period Improvement

Mon, 13 Apr 2026 09:00:00 -0400

CERRITOS, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, achieved $1.8 million in Medicare savings during Performance Period 3 of the Centers for Medicare & Medicaid Services’ Enhancing Oncology Model (EOM) through its California professional corporation, with savings equating to more than $6,400 per patient episode. This represents a significant increase from Performance Period 2, when TOI generated $1.1 million in savings, or more than $3,500 per episode.

For the second consecutive performance period, TOI earned the maximum score on avoidable emergency department visits

The Oncology Institute Achieves $1.8 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 3, Marking Significant Period-Over-Period Improvement

Mon, 13 Apr 2026 09:00:00 -0400

For the second consecutive performance period, TOI earned the maximum score on avoidable emergency department visits

The Oncology Institute Achieves $1.8 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 3, Marking Significant Period-Over-Period Improvement

Mon, 13 Apr 2026 09:00:00 -0400

For the second consecutive performance period, TOI earned the maximum score on avoidable emergency department visits